BCL-2家族凋亡调控作用及其介导的抗肿瘤药物治疗后耐药的研究进展  

Research progress of BCL-2 family apoptotic regulation and its mediated drug resistance after antitumor drug therapy

作　　者：陈骢 郝健淇 彭皓宁 刘伦旭[1,2] CHEN Cong;HAO Jianqi;PENG Haoning;LIU Lunxu(Department of Thoracic Surgery,West China Hospital,Sichuan University,Chengdu,610041,P.R.China;Chest Oncology Institute,West China Hospital,Sichuan University,Chengdu,610041,P.R.China)

机构地区：[1]四川大学华西医院胸外科,成都610041 [2]四川大学华西医院胸部肿瘤研究所,成都610041

出　　处：《中国胸心血管外科临床杂志》2023年第1期140-148,共9页Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

基　　金：国家博士后项目(2020TQ0210);四川大学华西医院专职博士后研发基金(2020HXBH108);四川大学华西医院1·3·5优秀学科项目(ZYGD18021)。

摘　　要：细胞凋亡是调节细胞增殖繁衍、维持机体稳态的重要手段。近年研究表明B细胞淋巴瘤-2(B-cell lymphoma-2,BCL-2)家族不仅是正常细胞凋亡程序调控的主导者,也是由凋亡逃逸方式介导的肿瘤发生、进展及后续药物治疗耐药性形成的主要参与者。BCL-2家族拮抗肿瘤药物诱导的细胞凋亡效应进而产生耐药性的现象已经在血液淋巴系统肿瘤、乳腺癌、肺癌、胃癌等疾病的临床治疗中被报道。随着研究的深入,针对BCL-2家族中发挥抗凋亡功能成员的特异性抑制剂也应运而生。本文系统地阐述了BCL-2家族介导的凋亡调控作用及其引起的肿瘤药物治疗耐药现象,同时总结BCL-2家族抑制剂最新研究进展,为解决未来肿瘤治疗抵抗、寻找治疗新靶点提供新思路。Apoptosis is an important means to regulate cell proliferation and maintain homeostasis.Recent researches have shown that the B-cell lymphoma-2(BCL-2)family not only plays a dominant role in the regulation of normal cell apoptosis,but also plays a crucial role in the formation of tumor genesis,progression and subsequent drug resistance mediated by the escape mode of apoptosis.The phenomenon that BCL-2 family antagonized the apoptosis induced by antitumor drugs and then acquired drug resistance has been reported in the clinical treatment of hematologic lymphatic system tumors,breast cancer,lung cancer,gastric cancer and other diseases.Thus,specific inhibitors targeting anti-apoptotic members of the BCL-2 family have emerged with the development of research.In this paper,we systematically reviewed the regulation of apoptosis mediated by BCL-2 family and the drug resistance mediated by BCL-2family.Meanwhile,we summarized the research advances of BCL-2 family specific inhibitors to provide new strategy for solving the problems on tumor therapeutic resistance and for finding new therapeutic targets in the future.

关 键 词：凋亡 BCL-2家族 抗肿瘤药物耐药 BCL-2家族抗凋亡成员特异性抑制剂 综述 

分 类 号：R979.1[医药卫生—药品]